Patrick and Charles Boyd bought more than $90 million of the illicit drugs and sold them to unwitting customers in South ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

Shares in the company rose on Wednesday morning as a result, lifting to their highest level for more than a year.

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...